Share Name Share Symbol Market Type Share ISIN Share Description
Amryt Pharma LSE:AMYT London Ordinary Share GB00BDD1LS57 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.125p -0.84% 14.75p 14.50p 15.00p 15.00p 14.75p 15.00p 41,017 13:05:17
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 11.4 -23.2 -10.4 - 31.98

Amryt Pharma Share Discussion Threads

Showing 3526 to 3544 of 3550 messages
Chat Pages: 142  141  140  139  138  137  136  135  134  133  132  131  Older
DateSubjectAuthorDiscuss
17/10/2018
19:09
Well today's RNS went down like a lead balloon! Just 41k of shares traded and a tiny rise in the share price that failed to hold. Unfortunately Lojuxta news is now generating no investor interest and it's beginning to look like the AMYT share price could have further to fall in the lead up to the EASE interim analysis scheduled for release in December. It's looking like the EASE trial is being priced to fail. Currently there is almost no investor interest in AMYT. I wonder why? Have investors got it right, or wrong? I'm currently down between 15-20% on my investment in FAST/AMYT. It looks like my only hope of a profit on my investment, anytime soon, is if the EASE trial is a resounding success. I should know my fate sometime in December. Fingers crossed!
papillon
17/10/2018
17:03
Excellent response to Bronxville on the lse bb. ignumvitae Posts: 175 Opinion: No Opinion Price: 15.00 KRYSTAL Today 08:11 Krystal's EB initial trial results are on just two adult patients. EB is a complex condition with many patient sub-sets. Krystal use an "off the shelf" gene therapy approach. They have just two programmes running & ZERO revenue. Nasdaq market cap is $200m or thereabouts. Their EB programme will require complete phase trials on larger populations with many potential missteps along the way. So take it two ways, either [1] don't get too beat up about Krystal & EB as regards Amryt OR [2] consider the potential value of Amryt's bespoke gene therapy.
papillon
17/10/2018
11:58
The answer to your question, mdalos is NO. Aegerion (Juxtapid/Lojuxta was their creation) tried that in the USA and they got themselves into some very hot water with the regulatory authorities as a consequence. It led to Aegerion being bailed out in a merger with QLT and a name change to Novelion. Novelion is having to deal with the financial burden of the penalties imposed on Aegerion as a consequence of it's errant, irresponsible, behaviour. Do some research on Aegerion/Novelion.
papillon
17/10/2018
11:47
https://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/AMYT/13831406.html Hypercholesterolaemia patients now could possibly lead to more general treatment for cholesterol issues across a broader Patient base at a later date ? Show us the money !!!
mdalos1
16/10/2018
20:14
Bronxville Posts: 529 Opinion: No Opinion Price: 14.875 RE: Kinda make AP101 obsolete Today 15:31 Well I'm glad I'm not heavily involved anymore but I'm convinced now these guys are peeing money down the drain.. Krystal's trial was tiny but a complete closure of wounds in 2 weeks is impressive.Who cares about the placebos if the actual trial is a 100% successful.The market is liking the results as well... If AMYT is forced to make the trial larger then they will have to dilute again.. Amryt dont have a hope in hell of finding other orphan pharmaceutical companies to partner with them due to their cash burn..Someone said 'too many high paid snouts in the trough' for such a small company.. I think Cathal Friel saw the writing on the wall and took what he could at the time... >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> Yes the wound healing time of KB103 was impressive, but it was just a 2 person trial. So many drugs sail through phase 1 & phase 2, but fail phase 3, either because they prove to be ineffective (futile), or worse still they prove to be dangerous and unsafe when the trial size is much, much, bigger than just 2 patients. Both FARN & IMM had drugs/treatments that sailed through phase 1 & 2 yet failed phase 3 with catastrophic effects on their respective sp's. Ask volsung, a poster on this bb, who had (unfortunately) shares in IMM. Regarding Jacksonpollacks comment about too many "snouts in the trough" he also says that about EDL. It's one of his common observations on AIM shares he holds, or has held. He specifically mentions the AMYT BoD, but there are only 2 execs on the BoD with their "snounts in the trough". There are 4 non execs on the BoD, but they can't be accused of having their "snouts in the trough". There are a further 6 members of the senior management team and they could have their "snouts in the trough" Cathal Friel could well have seen the "writing on the wall", but he still has 24 million, 697 thousand and 347 shares (24,697,347). That's 8.99% of AMYT shares in issue. According to the RNS dated 8th May 2018 he has signed a 2 year LOCK IN for those 24,697,347 shares after selling 8.38 million @ 17p per share. So, Bronxville, Cathal Friel still has a lot of skin left in the AMYT game! He's still got 75% of his original AMYT shareholding and has agreed that he can't sell them for around 18 months. Like you Bronxville I have no idea of what the EASE interim analysis, expected in December, will contain. I suggest we wait and see what the results of the analysis are and what recommendations are made. PS. Congratulations on your recent investment in Krystal Biotech, Bronxville. It's been very profitable. There's no doubt that investors liked the KB103 trial news, even though it was just a 2 person trial. I suspect that if Krystal Biotech were listed on AIM (like AMYT) instead of Nasdaq then it's share price and hence Mkt Cap would be much lower than it currently is.
papillon
15/10/2018
18:10
Bronxville Posts: 527 Opinion: No Opinion Price: 14.875 Kinda make AP101 obsolete Today 15:28 hTTps://finance.yahoo.com/news/krystal-biotech-announces-positive-interim-114500146.html KB103 is Krystal’s first "off-the-shelf", topical, gene therapy candidate to treat patients suffering from Dystrophic Epidermolysis Bullosa. Results on 2 patients met all primary efficacy (presence of functional COL7 expression, observation of NC1 and NC2 reactive anchoring fibrils and continued expression following repeat administration) and safety endpoints (no adverse events, inflammation or irritation) in topically administered KB103 wounds. With respect to secondary endpoints – topically administered KB103 wounds closed in 2 weeks and continue to stay closed to date. Topically administered placebo administered wounds took 10 weeks to close in patient 1 and did not completely close throughout the study in patient 2. >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> Big trial, Bronxville!!!! LOL. 2 patient trial; one on KB103 and one on a placebo (what was the placebo used?). KB103 might well make AP101 obsolete as a treatment for EB one day in the future, but how long in the future is that going to be? Judging by the size of the trial the "future" is still some way off!! Also will KB103 still prove to be successful in a much, much, larger phase III trial? Only time will tell. hTTp://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-positive-interim-results-placebo phase 1/2 study; anticipated completion H1 2019. Pivotal phase III study anticipated to start in H2 2019.
papillon
14/10/2018
21:27
"Turki Aldhakhil, the general manager of Al Arabiya, the official Saudi news channel, claimed in an opinion piece that Riyadh was ready to implement 30 measures “without flinching” the moment US sanctions were imposed, including cuts to oil production that could lead to prices rising to $100 a barrel." hTTps://www.theguardian.com/world/2018/oct/14/jamal-khashoggi-turkey-looks-to-uk-to-persuade-saudi-arabia-to-cooperate
papillon
14/10/2018
18:19
Fair points papillon. I sold AMYT at the right time, more out of frustration and luck than anything else. If you checkout and listen to sounds latest fireside chat and CEO pep talk you may well change your mind. Good luck to you here, but unless it drops significantly further, it's not for me anymore. As I said a long time ago here ... too many bod snouts in the trough ... and more waffle than the Brexit negotiations.
jacksonpollack
13/10/2018
17:11
Nothing's changed from my perspective.... It's still a dull Business with everything hinging on 1 thing... but the Markets generally have over-cooked the predictable drop by a significant % too, just this past week. As I predicted months ago this has dropped slowly down as it nears news of the interim analysis BUT if one assumes the Trial is continuing anyway because something positive is being witnessed generally (not reported from a Business perspective but witnessed from a trial perspective), then on the balance of probabilities the interim analysis news may well be of a positive nature and the only way is UP. That UP may well include an additional boost as the Markets themselves settle after last week's significant drops. At <15p and the potential to hit 21p on good new News this quarter, there's ~50% profit to be made... so why not take an extra "throw-away" gamble on a rainy day
mdalos1
13/10/2018
13:37
Bronxville Posts: 520 Opinion: No Opinion Price: 14.875 West coast of Ireland oil rush..Today 11:27 With all the activity off the west coast of Ireland it would have been better for this company to have stayed in oil. >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> Well there could be good news on that front, Bronxville, if you were on the FAST shareholder register on the 15/12/2015 because FAST's remaining O&G interests (extensive and expensive 3-D seismic offshore in the Celtic Sea and not that far from the Barryroe field) was put into a trust fund for FAST shareholders on the shareholders register on the 15/12/2015. Successful appraisal wells on Barryroe next year could rekindle interest in the Celtic Sea offshore of Cork and give that 3-D seismic some montary value.
papillon
12/10/2018
18:50
mdalos1 5 Oct '18 - 20:04 - 3382 of 3419 Cutting their losses... it's something people do... simply applying common sense to a rubbish situation mdalos1 9 Oct '18 - 15:38 - 3389 of 3419 It's an extraordinarily dull Business that is essentially an R&D outfit dabbling in a spot of witch-doctoring and snake-oil stuff. I'm almost fully resolved to AP101 being a resounding failure mdalos1 12 Oct '18 - 17:48 - 3416 of 3419 Bought a load more today.... this is a GIFT ! >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> LOL. You've CHANGED your tune! You've certainly had a "Road to Damascus conversion"! What caused this change of heart, mdalos? Time of the month? LOL.
papillon
12/10/2018
18:39
I think you are wise to limit your exposure papillion. Part of the problem with IMM was the blatant ramping going on with the insane valuations being quoted by certain parties. It all led to a bit of a bubble and I have to admit I got carried away with it. The analogy with wilfcat oilers is apt. I don’t mind missing a bit of the rise if P3 is a success. How much reaction in the share price if it fails given that the price is at lows presently?
volsung
12/10/2018
18:20
Blasted well hope it is a gift!!
bazworth
12/10/2018
18:20
Blasted well hope it is a gift!!
bazworth
12/10/2018
17:48
Bought a load more today.... this is a GIFT !
mdalos1
12/10/2018
16:34
I can understand your reluctance to gamble on the AP101 phase III EB trial result, volsung, following on for your painful experience with IMM. The IMM share price has fallen from over 150p per share 6 months ago to a current 11.5p per share. The share price fell off the edge of a cliff around 6 months ago when the bad news was released. I know nothing about IMM apart from that dramatic fall following the failure of it's phase III drug, volsung, however I suspect it's phase III drug trial was more high risk than that of AMYT's AP101 EASE phase III trial for EB if only because AP101 (Episalvan) already has regulatory approval for the treatment of PTW's (Partial Thickness Wounds) and as AMYT's illustrious chairman has pointed out in the past EB patients suffer from PTW's. PS. gambling on the outcome of phase III trial results has similarities with gambling on the results of wildcat oil wells. Both are very risky, speculative, investments where the CoS is often very low (often only 10-15% success rate in the case of wildcat oil wells even with the benefit of 3-D seismic) I can't predict the performance of the AMYT share price between now and the release in December of the EASE interim analysis data, but I wont be adding during that time. Why? Well I've set a limit to how much I'm prepared to gamble on AMYT and it's 25k shares (just under £5k in money terms). Of course AMYT keep on about securing other licenses for already approved orphan drugs, like Lojuxta, but so far they appear to have drawn a blank because there is only Lojuxta. I keep hoping they will announce another deal soon, but will they be able to secure one?
papillon
12/10/2018
15:51
Yes, volsung, Elliot Wave Theory shows that you will miss out on the initial rise following on from a good RNS in December (That's if we get a good RNS. A BIG IF!) by being cautious, but you should still have days (and maybe weeks) remaining in which to be able to profit from a good RNS. It will all depend on the size of the initial spike up on good news (assuming we get good news!) and how high the MM's open up the share price when the market opens following the RNS.
papillon
11/10/2018
23:35
I have to admire your persistance papillion. You sound like an intelligent bloke so I take what you say seriously. I have most of my pf in cash now so when the phase 3 results come out I will be waiting. Unfortunately my IMM experience means I can never invest pre Phase 3 again.
volsung
11/10/2018
22:59
True pap and green. Maybe it will come up roses. I still observe.
volsung
Chat Pages: 142  141  140  139  138  137  136  135  134  133  132  131  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20181017 18:17:43